English

Opus Genetics, Inc.

EDGAR

IRD Filing (144) · filed 2026-10-23

Annual consolidated revenue for 2025: about U001 14.2M, using the latest reported figures. The previous period, 2024, was about U001 10.99M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

755 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 755000 USD Source

Operating margin

-2,182.78%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -16480000 USD Source
Revenue: 755000 USD Source

Operating cash flow

-12 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -24677000 USD Source
Operating Cash Flow: -12727000 USD Source

Cash and cash equivalents: 88.8 million USD 2026-06-30 Source
Exact value

88812000 USD
Long-term debt including current maturities: 35.3 million USD 2026-06-30 Source
Exact value

35281000 USD
Shares outstanding: 82.6 million shares 2026-06-30 Source
Exact value

82647946 shares

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-23.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 2 of 11 periods available· newest 2020-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+29.1%

Prior period

U001 10.99 million

2024-01-01 – 2024-12-31
Current period

U001 14.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

14196000 − 10992000 = 3204000 U001

10992000 U001 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
14196000 U001 · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Opus Genetics, Inc. · 2025-12-31 Opus Genetics, Inc. (edgar:1228627) Year-over-year change in Revenue: 3204000 U001 Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 14196000 U001 (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1389444 Filing: 000114036126009247 Input fundies:Revenue: 10992000 U001 (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1390475 Filing: 000114036126009247
The citation records this snapshot. The page link may show a newer release later.
Net income
+U001 7.94 million

Prior period

−U001 57.53 million

2024-01-01 – 2024-12-31
Current period

−U001 49.59 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-49591000 − -57532000 = 7941000 U001

-57532000 U001 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-49591000 U001 · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Opus Genetics, Inc. · 2025-12-31 Opus Genetics, Inc. (edgar:1228627) Year-over-year change in Net income: 7941000 U001 Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -49591000 U001 (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1569476 Filing: 000114036126009247 Input fundies:NetIncome: -57532000 U001 (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1570529 Filing: 000114036126009247
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−U001 9.68 million

Prior period

−U001 25.58 million

2024-01-01 – 2024-12-31
Current period

−U001 35.25 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-35253000 − -25576000 = -9677000 U001

-25576000 U001 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-35253000 U001 · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Opus Genetics, Inc. · 2025-12-31 Opus Genetics, Inc. (edgar:1228627) Year-over-year change in Operating cash flow: -9677000 U001 Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -35253000 U001 (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1603462 Filing: 000114036126009247 Input fundies:OperatingCashFlow: -25576000 U001 (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1604480 Filing: 000114036126009247
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue U001 14.2 million 100% of revenue
Operating costs Derived U001 52.8 million 372% of revenue
Operating income −U001 38.6 million −272% of revenue
Tax, interest and other Derived U001 10.99 million 77% of revenue
Net income −U001 49.59 million −349% of revenue

Cash

Operating cash flow −U001 35.25 million −248% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 3,955% of revenue.
2022 45%54%
2023 Operating loss: operating costs were 155% of revenue.
2024 Operating loss: operating costs were 665% of revenue.
2025 Operating loss: operating costs were 372% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	0	19968000 Derived	-19968000	4652000 Derived	-24620000	-6797000 Derived	Source 2020-01-01 – 2020-12-31: 0 U001 Inspect Revenue Open source 2020-01-01 – 2020-12-31: -19968000 U001 Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -24620000 U001 Inspect Net Income Open source 2020-01-01 – 2020-12-31: -6797000 U001 Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 0 U001 Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	589000	23294000 Derived	-22705000	33988000 Derived	-56693000	Unavailable	Source 2021-01-01 – 2021-12-31: 589000 U001 Inspect Revenue Open source 2021-01-01 – 2021-12-31: -22705000 U001 Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -56693000 U001 Inspect Net Income Open source 2021-01-01 – 2021-12-31: -19370000 U001 Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	39850000	21624000 Derived	18226000	338000 Derived	17888000	Unavailable	Source 2022-01-01 – 2022-12-31: 39850000 U001 Inspect Revenue Open source 2022-01-01 – 2022-12-31: 18226000 U001 Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 17888000 U001 Inspect Net Income Open source 2022-01-01 – 2022-12-31: 14314000 U001 Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	19049000	29612000 Derived	-10563000	-577000 Derived	-9986000	Unavailable	Source 2023-01-01 – 2023-12-31: 19049000 U001 Inspect Revenue Open source 2023-01-01 – 2023-12-31: -10563000 U001 Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -9986000 U001 Inspect Net Income Open source 2023-01-01 – 2023-12-31: -1112000 U001 Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	10992000	73066000 Derived	-62074000	-4542000 Derived	-57532000	Unavailable	Source 2024-01-01 – 2024-12-31: 10992000 U001 Inspect Revenue Open source 2024-01-01 – 2024-12-31: -62074000 U001 Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -57532000 U001 Inspect Net Income Open source 2024-01-01 – 2024-12-31: -25576000 U001 Inspect Operating Cash Flow Open source
2025 2025-01-01 – 2025-12-31	14196000	52795000 Derived	-38599000	10992000 Derived	-49591000	Unavailable	Source 2025-01-01 – 2025-12-31: 14196000 U001 Inspect Revenue Open source 2025-01-01 – 2025-12-31: -38599000 U001 Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -49591000 U001 Inspect Net Income Open source 2025-01-01 – 2025-12-31: -35253000 U001 Inspect Operating Cash Flow Open source

Amounts are exact, in U001.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

U001 14.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(U001)	Source evidence
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	589000	Revenue: 589000 Open source
20222022-12-31	Revenue	39850000	Revenue: 39850000 Open source
20232023-12-31	Revenue	19049000	Revenue: 19049000 Open source
20242024-12-31	Revenue	10992000	Revenue: 10992000 Open source
20252025-12-31	Revenue	14196000	Revenue: 14196000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

29.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 589000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	6,665.7%	Revenue: 39850000 Open source Revenue: 589000 Open source
20232023-12-31	Year over year	-52.2%	Revenue: 19049000 Open source Revenue: 39850000 Open source
20242024-12-31	Year over year	-42.3%	Revenue: 10992000 Open source Revenue: 19049000 Open source
20252025-12-31	Year over year	29.1%	Revenue: 14196000 Open source Revenue: 10992000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -271.9% 2025

Net margin -349.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -19968000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-3,854.8%	Operating Income: -22705000 Open source Revenue: 589000 Open source
20222022-12-31	Operating margin	45.7%	Operating Income: 18226000 Open source Revenue: 39850000 Open source
20232023-12-31	Operating margin	-55.5%	Operating Income: -10563000 Open source Revenue: 19049000 Open source
20242024-12-31	Operating margin	-564.7%	Operating Income: -62074000 Open source Revenue: 10992000 Open source
20252025-12-31	Operating margin	-271.9%	Operating Income: -38599000 Open source Revenue: 14196000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -24620000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-9,625.3%	Net Income: -56693000 Open source Revenue: 589000 Open source
20222022-12-31	Net margin	44.9%	Net Income: 17888000 Open source Revenue: 39850000 Open source
20232023-12-31	Net margin	-52.4%	Net Income: -9986000 Open source Revenue: 19049000 Open source
20242024-12-31	Net margin	-523.4%	Net Income: -57532000 Open source Revenue: 10992000 Open source
20252025-12-31	Net margin	-349.3%	Net Income: -49591000 Open source Revenue: 14196000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -6797000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 589000 Open source Operating Cash Flow: -19370000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 39850000 Open source Operating Cash Flow: 14314000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 19049000 Open source Operating Cash Flow: -1112000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 10992000 Open source Operating Cash Flow: -25576000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 14196000 Open source Operating Cash Flow: -35253000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

U001 -35.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(U001)	Source evidence
20202020-12-31	Operating cash flow	-6797000	Operating Cash Flow: -6797000 Open source
20212021-12-31	Operating cash flow	-19370000	Operating Cash Flow: -19370000 Open source
20222022-12-31	Operating cash flow	14314000	Operating Cash Flow: 14314000 Open source
20232023-12-31	Operating cash flow	-1112000	Operating Cash Flow: -1112000 Open source
20242024-12-31	Operating cash flow	-25576000	Operating Cash Flow: -25576000 Open source
20252025-12-31	Operating cash flow	-35253000	Operating Cash Flow: -35253000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

U001 -6.8M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(U001)	Source evidence
20202020-12-31	Free cash flow	-6797000	Operating Cash Flow: -6797000 Open source Capital Expenditure: 0 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -19370000 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: 14314000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1112000 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -25576000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -35253000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	No source recorded
2021-12-31	Liabilities / assets	Not reported	No source recorded
2022-12-31	Liabilities / assets	Not reported	No source recorded
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Current assets / current liabilities	Not reported	No source recorded
2021-12-31	Current assets / current liabilities	Not reported	No source recorded
2022-12-31	Current assets / current liabilities	Not reported	No source recorded
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−U001 6.17 million Exact value Exact value: -6169000 U001 2019-01-01 – 2019-12-31: -6169000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2019-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: -6169000 U001 Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=U001&dimensions= Input fundies:NetIncome: -6169000 U001 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#403610 Filing: 000114036121008099 The citation records this snapshot. The page link may show a newer release later.	−U001 3.59 million Exact value Exact value: -3593000 U001 2019-01-01 – 2019-12-31: -3593000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2019-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: -3593000 U001 Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -3593000 U001 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#403189 Filing: 000114036121008099 The citation records this snapshot. The page link may show a newer release later.	U001 25,000 Exact value Exact value: 25000 U001 2019-01-01 – 2019-12-31: 25000 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Opus Genetics, Inc. · 2019-12-31 Opus Genetics, Inc. (edgar:1228627) Capital Expenditure: 25000 U001 Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 25000 U001 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#495732 Filing: 000114036121008099 The citation records this snapshot. The page link may show a newer release later.	−U001 3.62 million Calculation and evidence -3593000 − 25000 U001 Exact free cash flow: -3618000 U001 2019-01-01 – 2019-12-31: -3593000 U001 · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 25000 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Opus Genetics, Inc. · 2019-12-31 Opus Genetics, Inc. (edgar:1228627) Free cash flow: -3618000 U001 Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3593000 U001 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#403189 Filing: 000114036121008099 Input fundies:CapitalExpenditure: 25000 U001 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#495732 Filing: 000114036121008099 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−U001 24.62 million Exact value Exact value: -24620000 U001 2020-01-01 – 2020-12-31: -24620000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2020-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: -24620000 U001 Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=U001&dimensions= Input fundies:NetIncome: -24620000 U001 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036122011015/brhc10035368_10k.htm#1423705 Filing: 000114036122011015 The citation records this snapshot. The page link may show a newer release later.	−U001 6.8 million Exact value Exact value: -6797000 U001 2020-01-01 – 2020-12-31: -6797000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2020-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: -6797000 U001 Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -6797000 U001 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036122011015/brhc10035368_10k.htm#1463854 Filing: 000114036122011015 The citation records this snapshot. The page link may show a newer release later.	U001 0 Exact value Exact value: 0 U001 2020-01-01 – 2020-12-31: 0 U001 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Opus Genetics, Inc. · 2020-12-31 Opus Genetics, Inc. (edgar:1228627) Capital Expenditure: 0 U001 Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=U001&dimensions= Input fundies:CapitalExpenditure: 0 U001 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#495458 Filing: 000114036121008099 The citation records this snapshot. The page link may show a newer release later.	−U001 6.8 million Calculation and evidence -6797000 − 0 U001 Exact free cash flow: -6797000 U001 2020-01-01 – 2020-12-31: -6797000 U001 · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 0 U001 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Opus Genetics, Inc. · 2020-12-31 Opus Genetics, Inc. (edgar:1228627) Free cash flow: -6797000 U001 Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6797000 U001 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036122011015/brhc10035368_10k.htm#1463854 Filing: 000114036122011015 Input fundies:CapitalExpenditure: 0 U001 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/ocup-20201231.xml#495458 Filing: 000114036121008099 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−U001 56.69 million Exact value Exact value: -56693000 U001 2021-01-01 – 2021-12-31: -56693000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2021-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: -56693000 U001 Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=U001&dimensions= Input fundies:NetIncome: -56693000 U001 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036123014868/brhc10050364_10k.htm#1405192 Filing: 000114036123014868 The citation records this snapshot. The page link may show a newer release later.	−U001 19.37 million Exact value Exact value: -19370000 U001 2021-01-01 – 2021-12-31: -19370000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2021-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: -19370000 U001 Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -19370000 U001 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036123014868/brhc10050364_10k.htm#1433040 Filing: 000114036123014868 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	U001 17.89 million Exact value Exact value: 17888000 U001 2022-01-01 – 2022-12-31: 17888000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2022-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: 17888000 U001 Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=U001&dimensions= Input fundies:NetIncome: 17888000 U001 (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036124012399/ef20015277_10k.htm#1244155 Filing: 000114036124012399 The citation records this snapshot. The page link may show a newer release later.	U001 14.31 million Exact value Exact value: 14314000 U001 2022-01-01 – 2022-12-31: 14314000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2022-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: 14314000 U001 Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: 14314000 U001 (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036124012399/ef20015277_10k.htm#1269722 Filing: 000114036124012399 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−U001 9.99 million Exact value Exact value: -9986000 U001 2023-01-01 – 2023-12-31: -9986000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2023-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: -9986000 U001 Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=U001&dimensions= Input fundies:NetIncome: -9986000 U001 (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036125011410/ef20039022_10k.htm#1523780 Filing: 000114036125011410 The citation records this snapshot. The page link may show a newer release later.	−U001 1.11 million Exact value Exact value: -1112000 U001 2023-01-01 – 2023-12-31: -1112000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2023-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: -1112000 U001 Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -1112000 U001 (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036125011410/ef20039022_10k.htm#1553800 Filing: 000114036125011410 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−U001 57.53 million Exact value Exact value: -57532000 U001 2024-01-01 – 2024-12-31: -57532000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2024-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: -57532000 U001 Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=U001&dimensions= Input fundies:NetIncome: -57532000 U001 (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1570529 Filing: 000114036126009247 The citation records this snapshot. The page link may show a newer release later.	−U001 25.58 million Exact value Exact value: -25576000 U001 2024-01-01 – 2024-12-31: -25576000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2024-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: -25576000 U001 Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -25576000 U001 (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1604480 Filing: 000114036126009247 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−U001 49.59 million Exact value Exact value: -49591000 U001 2025-01-01 – 2025-12-31: -49591000 U001 Inspect Net Income Open source Share or cite Citation for Net Income · Opus Genetics, Inc. · 2025-12-31 Opus Genetics, Inc. (edgar:1228627) Net Income: -49591000 U001 Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=U001&dimensions= Input fundies:NetIncome: -49591000 U001 (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1569476 Filing: 000114036126009247 The citation records this snapshot. The page link may show a newer release later.	−U001 35.25 million Exact value Exact value: -35253000 U001 2025-01-01 – 2025-12-31: -35253000 U001 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Opus Genetics, Inc. · 2025-12-31 Opus Genetics, Inc. (edgar:1228627) Operating Cash Flow: -35253000 U001 Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:07:53Z Snapshot: ef16344d4d029a09d6ab041aa4e7f44f7b321f68dd0bf291a4a48ea9707b5617 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1228627/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=U001&dimensions= Input fundies:OperatingCashFlow: -35253000 U001 (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm#1603462 Filing: 000114036126009247 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

124 filings · 4,570 latest values · 4,570 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001228627, 1228627, IRD, OCUP, REXN, edgar:1228627, rnn

Also known as CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK, Ocuphire Pharma, Inc., Opus Genetics, Inc., REXAHN PHARMACEUTICALS, INC.

Opus Genetics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation